Headquartered in San Francisco, CA Fiscal year ends December NYSE: HIMS hims.com
Hims & Hers Health, Inc. (NYSE: HIMS) operates a consumer health and wellness platform. Through its websites and mobile applications, it provides access to personalized care, prescription and non-prescription products, medical consultation services, membership-based access, post-consultation support, and delivery of laboratory testing results.
A substantial majority of revenue is subscription-based. Customers are billed on a recurring basis for automatically delivered products and services. The company ended Q3 2026 with about 2.79 million subscribers and monthly revenue per average subscriber of $105.
The company operates in the United States and, increasingly, internationally. Rest of the World revenue exceeded $233 million in Q3 2026, following acquisitions that significantly expanded goodwill.
In 2026 it shifted its U.S. weight loss offering toward providing access to branded GLP-1 medications, with compounded GLP-1 medications offered only on a limited scale. It is also expanding treatments and specialties and rolling out an AI-native customer care experience. Updated
One of the most-followed voices in health and longevity now sits on the board of a $4.5 billion telehealth company fighting for credibility as regulators tighten the screws on compounded GLP-1s. That is a distribution and trust asset rivals cannot buy, and it lands while the weight-loss price war is still escalating.
Hims & Hers just landed Eli Lilly's branded GLP-1s on its platform, with self-pay pricing starting at $149 a month for Foundayo, and it agreed to stop offering compounded copies of Lilly's drugs. That swaps a legally shaky revenue stream for an authorized supply deal with the category leader.
Nearly 48 points separated the best and worst names in a 383-stock universe at the close, with Digital Turbine's 37% drop setting the floor. Take-Two's 8% gain came a day after its quarterly filing, while Hims & Hers kept sliding on its Q3 miss.
The Q3 earnings miss filed the night before outweighed the fresh Eli Lilly partnership, leaving the stock down 12% from its $22.11 open.
HIMS Q3 2026 earnings miss
Moves: Nov 10, 11:00 AM ET · Alpha Vantage quote
Digital Turbine has shed 37% of its value at the open, a wipeout no other name in the 386-stock priority list comes close to matching. Take-Two leads the other direction at nearly 9%, so the session's spread runs about 46 points wide.
Gross margin collapsed to 57% from 74% a year ago, turning 49% revenue growth into a loss where analysts modeled a profit. Management also trimmed full-year adjusted EBITDA guidance to $257 million to $277 million, so the international land grab is costing more than the top line implies.
The platform people can rely on for their health every day, in every category, and every market, is the platform that will transform the industry. We believe we are building that platform.
Dudum is asking investors to value a $5.1 billion company on breadth across every category and every market, looking past the weight-loss franchise that got it here. With GLP-1 pricing pressure and compounding rules tightening, the pitch rests on whether new categories scale fast enough to carry the story.
Hims & Hers is down 12.35% to $22.79 after announcing its expanded-access deal with Eli Lilly, with partner Eli Lilly up 3.36%. Traders are pricing the agreement as a margin concession rather than a volume win.
Hims & Hers Lilly deal press release
Moves: Nov 9, 3:40 PM ET · Alpha Vantage quote
Hims & Hers gave back nearly 10% from a $26 open on the day its Eli Lilly deal press release landed. Eli Lilly is up 3.08%, with the partnership not translating into credit for the telehealth side.
Hims & Hers Lilly deal press release
Moves: Nov 9, 2:40 PM ET · Alpha Vantage quote
Nearly 12% off the $26.25 open to $23.12 takes roughly $600 million off a $5.2 billion company in one session. Double-digit intraday swings are routine in this name, which is exactly why the close matters more than the dip.
A partial rebound is under way at Hims & Hers (NYSE:HIMS), even as the company’s legal fight with federal regulators extends. Hims & Hers stock is at $20.34 in afternoon trading, up…
A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%. The slide compounds a rough stretch,…
Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week. The drop comes four days after…
Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33…
Jeremy Phillips Live Updates Hims & Hers Q3 Earnings Coverage Wrap-Up4:36pm ETThat wraps up our initial coverage of HIMS’s Q3 results. Thank you for stopping by! HIMS Bull vs Bear Case After Tonight's Q3…
Thomas Richmond Shrinking revenue hasn’t kept Teladoc Health (NYSE:TDOC) from beating estimates on both sales and earnings. Early signs that its BetterHelp mental health business can shift toward insurance-covered care are giving investors a…
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like…
Hims and Hers Health heads into Q2 earnings carrying a brutal Q1 miss, margin compression, and a prediction market giving better than even odds on another stumble. Whether tonight's numbers vindicate the…
Thomas Richmond Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert,…
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults,…
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the…
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm…
David Moadel Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target…
David Moadel Live Updates HIMS Q1 Earnings Coverage Wrap-Up4:25pm ETThat wraps up our initial coverage of Hims and Hers Health’s Q1 results. Thank you for stopping by! Check out management’s earnings call at 5…
Thomas Richmond Hims & Hers Health, Inc. (NYSE: HIMS) operates a consumer health and wellness platform.
The Wall Street consensus 12-month price target for HIMS is $28.85.
